Centre Told To Decide On Cancer Drug At Low Price

KOCHI : The Kerala High Court on Tuesday directed the Union government to decide within one month whether it could intervene and make available a lifesaving medicine for breast cancer patients in the country at an affordable price.

“As per the available statistics, an alarming number of women succumb to breast cancer by reason of their inability to afford expensive treatment and medication. The right to life guaranteed under the Constitution, coupled with the State’s duty to improve public health, calls for emergent and effective action in the matter,” held the court.

The court was hearing a petition filed by a retired bank employee, diagnosed with HER2- Negative Metastatic Breast Cancer and is undergoing ‘targeted therapy’ treatment. The petitioner said she is receiving a monthly pension of ₹ 28,000 and the monthly cost of the medicines for her treatment comes to ₹63,480. One medicine, Ribociclib, alone costs ₹ 58,140 per month, she said.

Ribociclib is an imported medicine and if it’s manufactured in Inida the cost will come down substantially, the petitioner submitted.  Ribociclib presently enjoys a patent monopoly and its manufacturers are hence prevented from producing the medicine without the consent of the patent holder.

Section 92 of the Patents Act, 1970 provides for compulsory license and section 100 empowers the government to requisition lifesaving medicines in cases of extreme necessity, the petitioner said. Citing these, she had submitted a representation before various authorities requesting immediate action. She had received an acknowledgement from the Ministry of Women and Child Development that informed her that the representation is now before the Department for Promotion of Industry and Internal Trade (DPIIT).

  • Related Posts

    KGMU prof suspended for forcing patients to buy meds from pvt store

    Lucknow: Faculty member in the ophthalmology department of KGMU, Prof Sanjiv Gupta, was suspended on charges of prescribing medicines and lenses for cataract surgery that were available at a private…

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    New Delhi: The pharmacovigilance division of the Central drug regulator has received a total of 1,387 adverse reports, with the highest regarding fixed dose combinations (FDCs), and a total of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    KGMU prof suspended for forcing patients to buy meds from pvt store

    KGMU prof suspended for forcing patients to buy meds from pvt store

    World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

    World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

    NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

    Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

    Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

    DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports

    DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports